Virion Therapeutics has a total of 20 patents globally, out of which 2 have been granted. Of these 20 patents, more than 95% patents are active. The United States of America is where Virion Therapeutics has filed the maximum number of patents, followed by South Africa and Vietnam. Parallelly, Vietnam seems to be the main focused R&D centre while the United States of America is the origin country of Virion Therapeutics.
Virion Therapeutics was founded in 2018. Virion Therapeutics is a biotechnology company which is involved in development and marketing of vaccines for cancers and chronic viral infections.
Do read about some of the most popular patents of Virion Therapeutics which have been covered by us in this article and also you can find Virion Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Virion Therapeutics patent portfolio.
How many patents does Virion Therapeutics have?
Virion Therapeutics has a total of 20 patents globally. These patents belong to 3 unique patent families. Out of 20 patents, 19 patents are active.
How Many Patents did Virion Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Virion Therapeutics Applications Filed | Virion Therapeutics Patents Granted |
| 2023 | 2 | 1 |
| 2022 | 5 | 1 |
| 2021 | 13 | – |
How many Virion Therapeutics patents are Active/Inactive?
Worldwide Patents
How Many Patents did Virion Therapeutics File in Different Countries?
Countries in which Virion Therapeutics Filed Patents
| Country | Patent |
| United States Of America | 3 |
| South Africa | 2 |
| Viet Nam | 2 |
| New Zealand | 1 |
| Israel | 1 |
| Canada | 1 |
| Europe | 1 |
| Mexico | 1 |
| Hong Kong (S.A.R.) | 1 |
| Singapore | 1 |
| Brazil | 1 |
| China | 1 |
| India | 1 |
| Australia | 1 |
| Indonesia | 1 |
Where are Research Centers of Virion Therapeutics Patents Located?
What Percentage of Virion Therapeutics US Patent Applications Were Granted?
Virion Therapeutics (Excluding its subsidiaries) has filed 2 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1 have been granted leading to a grant rate of 100%.
Below are the key stats of Virion Therapeutics patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Virion Therapeutics?
| Law Firm | Total Applications | Success Rate |
| Bakerhostetler | 2 | 100% |
List of Virion Therapeutics patents
| Virion Therapeutics Patents | Title |
| US11850282B2 | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same |
| US11291716B2 | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same |
| US20230063089A1 | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same |
| EP4087605A1 | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same |
| CN115335076A | Adenoviral Vectors Encoding Hepatitis B Virus Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Use Thereof |
| ZA202310905A | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same |
| VN95665A | Adenovirut Vectors Encoding Hepatitis B Antibodies Fused With Glycoprotein D Of Virut Herpes And Methods Of Use There |
| VN94385A | Adenovirut Vectors Encoding Hepatitis B Antibodies Fused With Glycoprotein D Of Virut Herpes |
| ZA202207167A | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same |
| HK40082959A | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same |
| IN202217040049A | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoproteind And Methods Of Using The Same |
| ID202206559A | Vector Adenovirus Encounting Hepatitis B Virus Antigen Followed To Glycoprotein D Herpes Virus And Methods Using The Same Vector |
| MX2022008572A | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same. |
| BR112022013620A2 | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Use Thereof |
| SG11202251040KA | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same |
| IL294387A | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same |
| AU2021205936A1 | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same |
| NZ789990A | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same |
| CA3166989A1 | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same |
| WO2021142212A1 | Adenoviral Vectors Encoding Hepatitis B Viral Antigens Fused To Herpes Virus Glycoprotein D And Methods Of Using The Same |
What are Virion Therapeutics key innovation segments?
What Technologies are Covered by Virion Therapeutics?
The chart below distributes patents filed by Virion Therapeutics